Lundbeck sees hope in re-analysis of failed Phase III desmoteplase stroke trial
This article was originally published in Scrip
Executive Summary
A post-hoc analysis of the failed DIAS-2 Phase III study of Lundbeck's candidate for the treatment of ischaemic stroke, desmoteplase, suggests that the drug is effective in the sub-group of patients who suffered a serious stroke.